479628-50-7

Upstream product

• 109-04-6 2-bromo-pyridine 
• 1120-95-2 3-chloropyridazine 
• 1432795-28-2 2-pyridineboronic acid N-phenyldiethanolamine ester 
• 160427-24-7 4-Hydroxy-6-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one 
• 66317-38-2 6-(pyridine-2-yl)-2,3-dihydropyridazin-3-one 
• 1005036-22-5 potassium 2-hydroxy-4-oxo-4-(pyridin-2-yl)butanoate 
• 1122-62-9 2-acetylpyridine 
• 78784-70-0 3-chloro-6-(pyridin-2-yl)pyridazine 
• 813-19-4 bis(tri-n-butyltin) 

Relevant academic research and scientific papers

Influence of Hetero-Biaryl Ligands on the Photo-Electrochemical Properties of [ReINCS(N∩N)(CO)3]-Type Photosensitizers

A complete set of the symmetrical bidiazine (bdz) and asymmetrical pyridyldiazine (pydz) ligands, along with the known 2,2′-bipyridyl (bpy) ligand, and their respective rhenium(I)-tricarbonyl-bromo and -thiocyonato complexes are presented. A bathochromic shift is observed with an increasing number of nitrogen atoms, caused by a stabilization of the diimine based LUMO. As expected from the energy gap law, this results in an increase in the non-radiative decay constant (knr) along the line bpy-pydz-bdz. Interestingly, the increase in knr for both pyridazine ligands (2-(pyridin-2-yl)pyridazine (pypdz) and 3,3′-bipyridazine (bpdz)) is much less pronounced as compared to the other pydz resp. bdz ligands. This results in overall longer lifetime and quantum yield, at the increased spectral overlap with sunlight – both properties sought for in the creation of light-harvesting schemes in photochemistry.

INHIBITORS OF COLLAGEN PROLYL 4-HYDROXYLASE

Biheteroaryl dicarboxylates and esters, and salts thereof which are useful as modulators of CP4H activity and more particularly as inhibitors of CP4H. Compounds of formula: and salts thereof where: X is S, O, NH, or NR, where R is an alkyl group having 1-3 carbon atoms; R1 and R2 independently are —OR7, or —NHSO2R8, where R7 is selected from: hydrogen, alkyl, alkenyl, alkoxyalkyl, —R′—CO—R″, —R′—CO—O—R″, —CO—R″, —R′—O—CO—R″, —R′—CO—NR″, —CO—NR″, or —R′—O—CO—NR″, and R8 is selected from hydrogen, alkyl, aryl, arylalkyl; R3, R4 and R6 independently are hydrogen, alkyl, alkoxy, alkenyl, alkenoxy, halo alkyl, haloalkenyl, halogen, hydroxyl, hydroxyalkyl, hydroxyalkenyl, aryl, aryloxy, arylalkyl or arylalkyloxy; R5 is hydrogen, halogen, alkyl having 1-3 carbon atoms, or alkoxy having 1-3 carbon atoms; —R′— is a divalent straight chain or branched alkylene, and —R″ is an alkyl, alkenyl, arylalkyl, or aryl group. Methods for inhibition of CP4H in vivo and in vitro.

Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses

The present invention relates to nonlinear oligopyridazine compounds, to processes for obtaining them, to their uses, and also to their reduction to oligopyrroles and to the uses of the pyridazinylpyrrole and oligopyrrole compounds obtained. The invention relates in particular to the uses as medicaments, in particular for treating pathologies such as cancer, bacterial infections or parasitic infections, and also the uses in the materials, environmental, electronics and optics field.

LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS

The present invention relates to linear pyridazine compounds, and more particularly to those of these compounds which are oligopyridazine compounds, to processes for obtaining them, to their uses, and also to their reduction to pyrroles and to the uses of the pyrrole, pyridazinylpyrrole and oligopyrrole compounds obtained. The invention relates in particular to the uses as medicaments, in particular for treating pathologies such as cancer, bacterial infections or parasitic infections, and also the applications in the materials, environmental, electronics and optics field.

Pharmaceutical composition for treatment of cancer containing pyridylpyridazine or transition metal complex thereof as active ingredient

The present invention relates to a pharmaceutical composition for the treatment of cancer, which contains, as an active ingredient, a pyridylpyridazine compound or a transition metal complex thereof. As described above, the pyridylpyridazine compounds according to the present invention and the transition metal complexes thereof have anticancer activity and can be easily prepared at low cost. Thus, these compounds are useful as anticancer agents against various cancers, including lung cancer, adenocarcinoma, skin cancer, colon cancer, uterine cancer and brain cancer, which are expressed due to immune system abnormality.

PHARMACEUTICAL COMPOSITION FOR TREATING OF CANCER COMPRISING PYRIDYLPYRIDAZINE COMPOUNDS OR THEIR TRANSITION METAL COMPLEXES

The present invention relates to a pharmaceutical composition for the treatment of cancer, which contains, as an active ingredient, a pyridylpyridazine compound or a transition metal complex thereof. As described above, the pyridylpyridazine compounds according to the present invention and the transition metal complexes thereof have anticancer activity and can be easily prepared at low cost. Thus, these compounds are useful as anticancer agents against various cancers, including lung cancer, adenocarcinoma, skin cancer, colon cancer, uterine cancer and brain cancer, which are expressed due to immune system abnormality.